|
Insider Trading: Nastech Pharmaceutical Co Inc
Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Nastech Pharmaceutical Co Inc in the last 24 months are illustrated in figures 1 and 2. Table 1 shows the monthly insider trading data of Nastech Pharmaceutical Co Inc since year 2005. Table 2 shows the detailed insider transactions of Nastech Pharmaceutical Co Inc since 2005.
The reporting company's ticker symbol is MRNA.
The reporting company's CIK number is 737207.
The total value of stock buying since 2005 is $492,238.
The total value of stock sales is $5,246,147.
The total value of stock exercises is $1,948,393.
1 year stock price chart,
1 day stock price chart
opopp opopopop
Figure 1. Monthly insider transaction values at Nastech Pharmaceutical Co Inc (MRNA) in the past 24 months.
The trade values of insider stock buys, sales, and option exercises are in logarithmic scale
as shown on the right axis labels.
The detailed monthly and daily insider transactions are listed in the 2 tables below.
09 10 11 12 01 2007 02 03 04 05 06 07 08 09 10 11 12 01 2008 02 03 04 05 06 07 08 -
Figure 2. Average prices of insider buys, sales, and option exercises at Nastech Pharmaceutical Co Inc (MRNA) in the past 24 months. See table 2 for insider transaction details.
09 10 11 12 01 2007 02 03 04 05 06 07 08 09 10 11 12 01 2008 02 03 04 05 06 07 08 -
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises
for Nastech Pharmaceutical Co Inc (MRNA).
Trading Period
year-month |
Insider Buying
Shares Value ($) |
Insider Sales
Shares Value ($) |
Option Exercises
Shares Value ($) |
| 2008-08 | 10,000 | 7,615 | 0 | 0 | 0 | 0 |
| 2008-07 | 0 | 0 | 752 | 847 | 0 | 0 |
| 2008-05 | 60,000 | 71,565 | 0 | 0 | 0 | 0 |
| 2008-03 | 5,000 | 11,975 | 0 | 0 | 0 | 0 |
| 2007-12 | 2,000 | 8,080 | 0 | 0 | 0 | 0 |
| 2007-11 | 0 | 0 | 3,000 | 43,722 | 0 | 0 |
| 2007-10 | 0 | 0 | 4,500 | 64,715 | 0 | 0 |
| 2007-09 | 0 | 0 | 59,600 | 846,939 | 57,316 | 565,995 |
| 2007-08 | 0 | 0 | 35,558 | 510,624 | 35,351 | 330,884 |
| 2007-07 | 0 | 0 | 8,800 | 105,939 | 0 | 0 |
| 2007-06 | 0 | 0 | 9,400 | 107,095 | 0 | 0 |
| 2007-05 | 0 | 0 | 3,000 | 40,980 | 0 | 0 |
| 2007-04 | 0 | 0 | 11,850 | 147,271 | 5,000 | 54,950 |
| 2007-03 | 12,000 | 124,667 | 1,000 | 11,197 | 0 | 0 |
| 2007-02 | 0 | 0 | 12,130 | 149,227 | 5,000 | 48,200 |
| 2007-01 | 0 | 0 | 13,456 | 191,020 | 5,000 | 44,450 |
| 2006-12 | 2,200 | 34,577 | 8,675 | 146,579 | 5,000 | 54,950 |
| 2006-11 | 0 | 0 | 11,620 | 205,854 | 5,000 | 54,950 |
| 2006-10 | 3,000 | 47,250 | 13,836 | 214,123 | 5,000 | 54,950 |
| 2006-09 | 0 | 0 | 6,000 | 90,645 | 5,000 | 54,950 |
| 2006-08 | 0 | 0 | 12,702 | 175,955 | 5,000 | 50,450 |
| 2006-07 | 0 | 0 | 6,700 | 103,739 | 5,000 | 44,450 |
| 2006-06 | 0 | 0 | 27,460 | 387,795 | 25,000 | 209,450 |
| 2006-05 | 3,000 | 39,390 | 8,500 | 121,968 | 5,000 | 44,450 |
| 2006-04 | 0 | 0 | 13,767 | 227,966 | 2,667 | 26,083 |
| 2006-03 | 5,000 | 84,316 | 27,402 | 505,821 | 14,167 | 116,711 |
| 2006-02 | 0 | 0 | 13,700 | 260,721 | 10,000 | 82,100 |
| 2006-01 | 0 | 0 | 18,000 | 264,463 | 10,000 | 64,170 |
| 2005-12 | 0 | 0 | 13,000 | 198,302 | 10,000 | 46,250 |
| 2005-11 | 0 | 0 | 1,000 | 13,043 | 0 | 0 |
| 2005-10 | 0 | 0 | 1,000 | 14,119 | 0 | 0 |
| 2005-09 | 0 | 0 | 1,000 | 13,889 | 0 | 0 |
| 2005-08 | 0 | 0 | 1,000 | 14,597 | 0 | 0 |
| 2005-07 | 0 | 0 | 1,000 | 14,190 | 0 | 0 |
| 2005-06 | 0 | 0 | 2,225 | 28,354 | 0 | 0 |
| 2005-05 | 0 | 0 | 1,000 | 10,392 | 0 | 0 |
| 2005-04 | 4,300 | 43,803 | 1,000 | 10,056 | 0 | 0 |
| 2005-03 | 2,000 | 19,000 | 400 | 4,000 | 0 | 0 |
Table 2. Detailed insider stock purchases, sales, and option exercises
for Nastech Pharmaceutical Co Inc (MRNA)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2008-08-11 | French J Michael (CEO) | Purchase | 10,000 | .76 | 7,615 |
| 2008-07-14 | Costantino Henry R (CSO - Delivery) | Sale | 231 | 1.01 | 233 |
| 2008-07-02 | Costantino Henry R (CSO - Delivery) | Sale | 240 | 1.17 | 280 |
| 2008-07-01 | Costantino Henry R (CSO - Delivery) | Sale | 81 | 1.19 | 96 |
| 2008-07-01 | Duffy Timothy M (Chief Business Officer) | Sale | 200 | 1.19 | 238 |
| 2008-05-13 | Thaw Bruce R/fa (Director) | Purchase | 50,000 | 1.20 | 60,166 |
| 2008-05-12 | Stanewick Gerald T (Director) | Purchase | 10,000 | 1.14 | 11,399 |
| 2008-03-19 | Stanewick Gerald T (Director) | Purchase | 5,000 | 2.40 | 11,975 |
| 2007-12-07 | York Bruce R (Chief Actg Officer, Asst Sec.) | Purchase | 2,000 | 4.04 | 8,080 |
| 2007-11-01 | Wenig Devin (Director) | Sale | 3,000 | 14.57 | 43,722 |
| 2007-10-09 | Wenig Devin (Director) | Sale | 1,500 | 16.02 | 24,037 |
| 2007-10-01 | Wenig Devin (Director) | Sale | 3,000 | 13.56 | 40,678 |
| 2007-09-27 | Quay Steven C (Chairman, President and CEO) | Sale | 5,200 | 13.57 | 70,566 |
| 2007-09-10 | Stanewick Gerald T (Director) | Sale | 4,200 | 14.21 | 59,695 |
| 2007-09-06 | Johnson Paul H (Sr VP of R&D, CSO) | Sale | 47,200 | 14.30 | 674,969 |
| 2007-09-06 | Johnson Paul H (Sr VP of R&D, CSO) | Option Exercise | 57,316 | 9.88 | 565,995 |
| 2007-09-04 | Wenig Devin (Director) | Sale | 3,000 | 13.90 | 41,709 |
| 2007-08-23 | Johnson Paul H (Sr VP of R&D, CSO) | Sale | 1,100 | 14.30 | 15,733 |
| 2007-08-23 | Johnson Paul H (Sr VP of R&D, CSO) | Option Exercise | 1,339 | 9.36 | 12,533 |
| 2007-08-22 | Johnson Paul H (Sr VP of R&D, CSO) | Sale | 20,558 | 14.30 | 293,979 |
| 2007-08-22 | Johnson Paul H (Sr VP of R&D, CSO) | Option Exercise | 28,058 | 9.36 | 262,622 |
| 2007-08-21 | Johnson Paul H (Sr VP of R&D, CSO) | Sale | 3,900 | 14.50 | 56,550 |
| 2007-08-21 | Johnson Paul H (Sr VP of R&D, CSO) | Option Exercise | 5,954 | 9.36 | 55,729 |
| 2007-08-15 | Holubiak Myron Z (Director) | Sale | 3,000 | 14.19 | 42,567 |
| 2007-08-08 | Wenig Devin (Director) | Sale | 4,000 | 16.00 | 64,019 |
| 2007-08-01 | Wenig Devin (Director) | Sale | 3,000 | 12.59 | 37,776 |
| 2007-07-25 | Quay Steven C (Chairman, President and CEO) | Sale | 5,800 | 12.24 | 70,963 |
| 2007-07-10 | Wenig Devin (Director) | Sale | 2,000 | 12.02 | 24,040 |
| 2007-07-02 | Wenig Devin (Director) | Sale | 1,000 | 10.94 | 10,936 |
| 2007-06-07 | Quay Steven C (Chairman, President and CEO) | Sale | 6,400 | 11.05 | 70,723 |
| 2007-06-01 | Wenig Devin (Director) | Sale | 3,000 | 12.12 | 36,372 |
| 2007-05-07 | Wenig Devin (Director) | Sale | 3,000 | 13.66 | 40,980 |
| 2007-04-20 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 13.22 | 66,109 |
| 2007-04-20 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 10.99 | 54,950 |
| 2007-04-18 | Quay Steven C (Chairman, President and CEO) | Sale | 5,850 | 12.04 | 70,414 |
| 2007-04-02 | Wenig Devin (Director) | Sale | 1,000 | 10.75 | 10,748 |
| 2007-03-09 | Beese J Carter Jr (Director) | Purchase | 8,000 | 10.21 | 81,700 |
| 2007-03-08 | Stanewick Gerald T (Director) | Purchase | 2,000 | 10.73 | 21,467 |
| 2007-03-08 | Beese J Carter Jr (Director) | Purchase | 2,000 | 10.75 | 21,500 |
| 2007-03-01 | Wenig Devin (Director) | Sale | 1,000 | 11.20 | 11,197 |
| 2007-02-27 | Quay Steven C (Chairman, President and CEO) | Sale | 6,130 | 11.50 | 70,523 |
| 2007-02-07 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 13.12 | 65,596 |
| 2007-02-07 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 9.64 | 48,200 |
| 2007-02-01 | Wenig Devin (Director) | Sale | 1,000 | 13.11 | 13,108 |
| 2007-01-25 | Quay Steven C (Chairman, President and CEO) | Sale | 5,250 | 13.43 | 70,490 |
| 2007-01-04 | Ranker Philip C (Chief Financial Officer) | Sale | 2,206 | 14.58 | 32,163 |
| 2007-01-04 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 14.69 | 73,469 |
| 2007-01-04 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 8.89 | 44,450 |
| 2007-01-03 | Wenig Devin (Director) | Sale | 1,000 | 14.90 | 14,898 |
| 2006-12-22 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 675 | 15.67 | 10,577 |
| 2006-12-11 | Stanewick Gerald T (Director) | Purchase | 1,423 | 15.67 | 22,301 |
| 2006-12-08 | Stanewick Gerald T (Director) | Purchase | 777 | 15.80 | 12,276 |
| 2006-12-05 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 16.18 | 80,912 |
| 2006-12-05 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 10.99 | 54,950 |
| 2006-12-01 | Wenig Devin (Director) | Sale | 3,000 | 18.36 | 55,090 |
| 2006-11-15 | Quay Steven C (Chairman, President and CEO) | Sale | 3,620 | 19.56 | 70,819 |
| 2006-11-03 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 16.45 | 82,263 |
| 2006-11-03 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 10.99 | 54,950 |
| 2006-11-01 | Wenig Devin (Director) | Sale | 3,000 | 17.59 | 52,772 |
| 2006-10-10 | Wenig Devin (Director) | Sale | 2,000 | 16.00 | 32,000 |
| 2006-10-09 | Quay Steven C (Chairman, President and CEO) | Sale | 5,175 | 15.62 | 80,808 |
| 2006-10-06 | Stanewick Gerald T (Director) | Purchase | 3,000 | 15.75 | 47,250 |
| 2006-10-05 | Johnson Paul H (Sr VP of R&D, CSO) | Sale | 661 | 15.54 | 10,271 |
| 2006-10-04 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 15.14 | 75,709 |
| 2006-10-04 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 10.99 | 54,950 |
| 2006-10-02 | Wenig Devin (Director) | Sale | 1,000 | 15.34 | 15,335 |
| 2006-09-06 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 15.10 | 75,521 |
| 2006-09-06 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 10.99 | 54,950 |
| 2006-09-01 | Wenig Devin (Director) | Sale | 1,000 | 15.12 | 15,124 |
| 2006-08-11 | York Bruce R (Other) | Sale | 882 | 14.23 | 12,550 |
| 2006-08-08 | Quay Steven C (Chairman, President and CEO) | Sale | 5,820 | 13.88 | 80,766 |
| 2006-08-03 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 13.85 | 69,263 |
| 2006-08-03 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 10.09 | 50,450 |
| 2006-08-01 | Wenig Devin (Director) | Sale | 1,000 | 13.38 | 13,376 |
| 2006-07-06 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 15.43 | 77,125 |
| 2006-07-06 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 8.89 | 44,450 |
| 2006-07-05 | Wenig Devin (Director) | Sale | 500 | 16.00 | 8,000 |
| 2006-07-03 | Duffy Timothy M (Exec. VP of Business Devp) | Sale | 200 | 15.58 | 3,116 |
| 2006-07-03 | Wenig Devin (Director) | Sale | 1,000 | 15.50 | 15,498 |
| 2006-06-28 | Duffy Timothy M (Exec. VP of Business Devp) | Sale | 1,460 | 14.81 | 21,622 |
| 2006-06-08 | Wenig Devin (Director) | Sale | 2,000 | 13.68 | 27,360 |
| 2006-06-08 | Wenig Devin (Director) | Option Exercise | 2,000 | 8.25 | 16,500 |
| 2006-06-07 | Thaw Bruce R/fa (Director) | Sale | 10,000 | 14.00 | 140,000 |
| 2006-06-07 | Thaw Bruce R/fa (Director) | Option Exercise | 10,000 | 8.25 | 82,500 |
| 2006-06-05 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 14.81 | 74,045 |
| 2006-06-05 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 8.89 | 44,450 |
| 2006-06-05 | Wenig Devin (Director) | Sale | 8,000 | 13.84 | 110,742 |
| 2006-06-05 | Wenig Devin (Director) | Option Exercise | 8,000 | 8.25 | 66,000 |
| 2006-06-01 | Wenig Devin (Director) | Sale | 1,000 | 14.03 | 14,026 |
| 2006-05-26 | Wormuth David E (Sr VP, Operations & Mfg) | Sale | 2,500 | 13.58 | 33,956 |
| 2006-05-16 | Michelson Leslie D (Director) | Purchase | 3,000 | 13.13 | 39,390 |
| 2006-05-11 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 5,000 | 14.57 | 72,851 |
| 2006-05-11 | Brandt Gordon (Exec VP of Science and Clinica) | Option Exercise | 5,000 | 8.89 | 44,450 |
| 2006-05-01 | Wenig Devin (Director) | Sale | 1,000 | 15.16 | 15,161 |
| 2006-04-25 | Quay Steven C (Chairman, President and CEO) | Sale | 5,100 | 15.75 | 80,346 |
| 2006-04-11 | Quay Steven C (Chairman, President and CEO) | Sale | 2,667 | 15.83 | 42,218 |
| 2006-04-11 | Quay Steven C (Chairman, President and CEO) | Option Exercise | 2,667 | 9.78 | 26,083 |
| 2006-04-05 | Stanewick Gerald T (Director) | Sale | 3,000 | 17.25 | 51,750 |
| 2006-04-03 | Wenig Devin (Director) | Sale | 3,000 | 17.88 | 53,652 |
| 2006-03-29 | Pollock John V (Director) | Sale | 10,000 | 17.86 | 178,599 |
| 2006-03-28 | Pollock John V (Director) | Option Exercise | 10,000 | 8.25 | 82,500 |
| 2006-03-27 | Brandt Gordon (Exec VP of Science and Clinica) | Sale | 1,685 | 18.34 | 30,902 |
| 2006-03-22 | Wormuth David E (Sr VP, Operations & Mfg) | Sale | 4,167 | 16.75 | 69,808 |
| 2006-03-22 | Wormuth David E (Sr VP, Operations & Mfg) | Option Exercise | 4,167 | 8.21 | 34,211 |
| 2006-03-22 | Michelson Leslie D (Director) | Purchase | 5,000 | 16.86 | 84,316 |
| 2006-03-16 | Quay Steven C (Chairman, President and CEO) | Sale | 4,950 | 16.17 | 80,041 |
| 2006-03-01 | Wenig Devin (Director) | Sale | 6,600 | 22.19 | 146,471 |
| 2006-02-23 | Wenig Devin (Director) | Sale | 3,600 | 20.19 | 72,670 |
| 2006-02-22 | Wormuth David E (Sr VP, Operations & Mfg) | Sale | 10,000 | 18.70 | 186,172 |
| 2006-02-22 | Wormuth David E (Sr VP, Operations & Mfg) | Option Exercise | 10,000 | 8.21 | 82,100 |
| 2006-01-27 | Wenig Devin (Director) | Sale | 2,000 | 16.00 | 32,000 |
| 2006-01-23 | Wormuth David E (Sr VP, Operations &) | Sale | 10,000 | 14.58 | 145,780 |
| 2006-01-23 | Wormuth David E (Sr VP, Operations &) | Option Exercise | 10,000 | 6.42 | 64,170 |
| 2006-01-03 | Wenig Devin (Director) | Sale | 1,000 | 14.61 | 14,608 |
| 2005-12-22 | Wormuth David E (Sr VP, Operations &) | Sale | 10,000 | 15.19 | 151,940 |
| 2005-12-22 | Wormuth David E (Sr VP, Operations &) | Option Exercise | 10,000 | 4.62 | 46,250 |
| 2005-12-07 | Wenig Devin (Director) | Sale | 2,000 | 16.03 | 32,060 |
| 2005-12-01 | Wenig Devin (Director) | Sale | 1,000 | 14.30 | 14,302 |
| 2005-11-01 | Wenig Devin (Director) | Sale | 1,000 | 13.04 | 13,043 |
| 2005-10-03 | Wenig Devin (Director) | Sale | 1,000 | 14.12 | 14,119 |
| 2005-09-01 | Wenig Devin (Director) | Sale | 1,000 | 13.89 | 13,889 |
| 2005-08-01 | Wenig Devin (Director) | Sale | 1,000 | 14.60 | 14,597 |
| 2005-07-01 | Wenig Devin (Director) | Sale | 1,000 | 14.19 | 14,190 |
| 2005-06-16 | Duffy Timothy M (VP of Business Devp) | Sale | 1,225 | 13.24 | 16,219 |
| 2005-06-01 | Wenig Devin (Director) | Sale | 1,000 | 12.14 | 12,135 |
| 2005-05-02 | Wenig Devin (Director) | Sale | 1,000 | 10.39 | 10,392 |
| 2005-04-14 | Michelson Leslie D (Director) | Purchase | 3,000 | 10.29 | 30,869 |
| 2005-04-06 | Wenig Devin (Director) | Sale | 1,000 | 10.06 | 10,056 |
| 2005-04-04 | Stanewick Gerald T (Director) | Purchase | 1,300 | 9.95 | 12,934 |
| 2005-03-18 | Stanewick Gerald T (Director) | Purchase | 2,000 | 9.50 | 19,000 |
| 2005-03-10 | Wenig Devin (Director) | Sale | 400 | 10.00 | 4,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Nastech Pharmaceutical Co Inc (symbol MRNA,
CIK number 737207) see
the Securities and Exchange Commission (SEC) website.
|
|
